IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter
Medtronic, Inc. · Decision date Sep 24, 2026
What did the FDA decide?
The FDA record P140010/S106, dated 2026-09-24 with decision OK30, is a 30-day notice for a process change under the manufacturer, sterilizer, packager or supplier category. The stated scope is approval of a change to the in-process testing strategy and sample size for balloon burst testing, proximal weld tensile strength testing, and distal tip weld tensile testing of the IN.PACT DCB 018 catheter.
The applicant is Medtronic, Inc.; the product code is ONU and the device category is drug-eluting peripheral transluminal angioplasty catheter. The source statement identifies three distinct test areas, but it does not give the prior or revised sample sizes, the test methods, or any supporting performance results, and it does not establish safety or clinical effectiveness. The record does not describe the original PMA scope beyond this supplement relationship.
FDA approval order statement
approval for a change to the in-process testing strategy and sample size for balloon burst testing, proximal weld tensile strength testing, and distal tip weld tensile of the IN.PACT DCB 018 catheter
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 24, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P140010/S106
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- ONU
- Decision code
- OK30
- Decision date
- Sep 24, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Drug-Eluting Peripheral Transluminal Angioplasty Catheter.
- Applicant
- Medtronic, Inc.
- Product code
- ONU
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P140010. Subsequent supplements may change the device or its indications.
FDA decision timeline
P140010 · Original PMA
IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter and IN.PACT 018 Paclitax
P140010/S106 received
Application receipt date recorded by FDA.
P140010/S106 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P140010. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P140010
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA approval | Dec 30, 2014 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3576 Unocal Pl., Santa Rosa, CA, 95403
Sources and methodology
- Original FDA record: P140010/S106
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records